University of Lisbon (Portugal)
Helena F Florindo graduated in Pharmaceutical Sciences in 2003 (University of Lisbon) and obtained her Ph.D. degree in Pharmaceutical Technology in 2008 (University of Lisbon), in collaboration with the University of London. Currently, she is an Assistant Professor Dr. Habil at the Faculty of Pharmacy, University of Lisbon. She is the Group Leader of the BioNanoSciences ñ Drug Delivery & Immunotherapy research group, at the Research Institute for Medicines. She is also a Member of the Portuguese Medicines Evaluation Board (CAM) and Diretor of the SPLC-CRS. Both nanotechnology and immune-oncology fields have motivated her multidisciplinary research focused on the rational development of functionalized nanobiomaterials as novel immunotherapies for cancer treatment. It includes the characterization of the anti-tumour effects induced by the combination of nano-vaccines with nano-therapeutics designed to modulate the functions of key cells within tumour microenvironment, such as T cells, myeloid-derived cells and tumour cells.